FDA-Approved Cancer Drug Doxorubicin Shows Promise Against Drug-Resistant Herpes Infections
核心洞察
University of Illinois Chicago (搜索) researchers discovered that doxorubicin, an FDA-approved chemotherapy drug, can effectively block drug-resistant herpes simplex virus type 1 (搜索) (HSV-1 (搜索)) infections in laboratory studies.
The drug works by targeting the PI3K-AKT-mTOR (搜索) pathway in human cells rather than the virus directly, potentially reducing the likelihood of resistance development.
Doxorubicin demonstrated effectiveness against acyclovir-resistant HSV-1 (搜索) strains and showed synergistic effects when combined with existing antivirals, allowing for lower dosing.
University of Illinois Chicago (搜索) researchers have identified a promising new application for doxorubicin, a widely used chemotherapy drug, in treating drug-resistant herpes simplex virus type 1 (搜索) (HSV-1 (搜索)) infections. The discovery, published in Drug Resistance Updates, represents a potential breakthrough for patients facing limited treatment options when standard antivirals lose effectiveness.
"This opens up an unexpected, potentially fast-moving path toward treating drug-resistant herpes infections," said Deepak Shukla, a virologist in the College of Medicine at UIC and study leader. "HSV-1 (搜索) infections have serious, sometimes life-threatening consequences, and this drug may help save lives."
Novel Mechanism Targets Host Pathways
Unlike traditional antiviral drugs that attack the virus directly, doxorubicin works by disrupting the PI3K-AKT-mTOR (搜索) pathway within human cells. This cellular pathway, which regulates cell growth and survival, is hijacked by HSV-1 (搜索) to enter cells and establish infection.
"We were excited to see how doxorubicin halts the virus at its source," said postdoctoral researcher and first author Pankaj Sharma. By targeting the host cell rather than the virus itself, this approach may reduce the likelihood of resistance development, as viral mutations typically allow escape from drugs that target viral machinery directly.
Comprehensive Testing Across Multiple Models
The research team evaluated doxorubicin's antiviral activity across several experimental systems, including human cell cultures, tissue models, and mouse studies. The drug consistently blocked HSV-1 (搜索) infection across multiple viral strains, including those resistant to acyclovir, the standard antiviral treatment.
Importantly, doxorubicin demonstrated synergistic effects when combined with existing antivirals. When paired with acyclovir, the combination enhanced overall antiviral activity while allowing for lower doses of acyclovir, which can cause kidney damage at high concentrations.
Addressing Critical Clinical Need
HSV-1 (搜索) infects billions of people worldwide and remains dormant in nerve cells for life. While many infected individuals experience only cold sores, immunocompromised patients face severe complications including brain inflammation (搜索) and organ failure (搜索). Drug-resistant strains pose particular challenges in these vulnerable populations, where treatment options become limited and often more toxic.
"Immunocompromised patients, including cancer (搜索) patients, are especially vulnerable to HSV-1 (搜索) infection, which can cause brain inflammation (搜索) and organ failure (搜索) when left untreated," the researchers noted. "Drug-resistant strains are especially difficult to eradicate."
Computational Discovery Platform
The identification of doxorubicin emerged from HerpDock, a computational screening tool developed by Shukla's team in 2024. This system analyzes large numbers of chemical compounds to identify potential antiviral candidates by examining molecular interactions with viral processes.
"We were excited when we realized that doxorubicin is already FDA-approved," Shukla said. "That matters because its safety profile and dosing are already well-understood. This drug could reach clinicians and patients much faster than a brand-new discovery."
Dual Benefits for Cancer Patients
The discovery may offer particular advantages for cancer (搜索) patients, who already receive doxorubicin as part of their treatment regimen. These patients face elevated risks from HSV-1 (搜索) infections due to their compromised immune systems, and the dual application could provide protection against both cancer progression and viral complications.
"I enjoyed being a part of something that can really help people," said Divya Kapoor, a coauthor and UIC graduate student researcher. "This discovery has the potential to prevent herpes-related deaths and improve patient outcomes around the world, including for cancer (搜索) patients who use doxorubicin."
Implications for Future Antiviral Development
The research highlights a broader shift toward host-targeted antiviral therapies, which may prove more difficult for viruses to evade through mutation. This approach could inform treatment strategies for other persistent viral infections beyond HSV-1 (搜索).
The study's success also demonstrates the value of drug repurposing strategies, which can accelerate the path to clinical application by leveraging existing safety and dosing data. If confirmed in clinical trials, this approach could provide physicians with new treatment options for drug-resistant herpes infections significantly faster than developing entirely new medications.